INS and Hypoglycemia: Randomised controlled trials have consistently demonstrated that once‐weekly insulin efsitora alfa achieves HbA1c reductions comparable to those of daily insulin (glargine or degludec), while also reducing hypoglycemia risk, limiting dose adjustments, and simplifying titration [14, 15].